非编码RNA在糖尿病心肌病中的研究进展

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (610 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Diabetic cardiomyopathy (DCM) is one of the important causes of death in diabetic patients. It is defined as a ventricular dysfunction disease independent of coronary artery disease and hypertension. It is defined as ventricular dysfunction independent of coronary artery disease and hypertension， it can induce heart failure, malignant arrhythmia and other heart disease, there is also a risk of sudden cardiac death. Cardiac tissue in DCM patients often undergoes multiple morphological changes at the cellular level, such as cardiomyocyte hypertrophy, interstitial fibrosis, and intramyocardial microvascular disease. Non-coding RNAs (ncRNAs) play an important role in this process. This paper summarizes some of the current literature on ncRNAs in DCM studies. To explore the use of long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) as therapeutic targets and biomarkers for DCM, and provide new ideas and new horizons for the specific treatment of DCM.

Key words： Diabetic cardiomyopathy Non-coding RNAs Long non-coding RNAs MicroRNAs

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TAN Zhongyue SUN Yuehang JIAO Lei ZHANG Ying WANG Zhiguo

Cite this article:

TAN Zhongyue SUN Yuehang JIAO Lei ZHANG Ying WANG Zhiguo. Research progress of non-coding RNA in diabetic cardiomyopathy[J]. 中国医药导报, 2019, 16(36): 33-36.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I36/33

[1] Abdulle LE，Hao JL，Pant OP，et al. MALAT1 as a Diagnostic and Therapeutic Target in Diabetes-Related Complications：A Promising Long-Noncoding RNA [J]. Int J Med Sci，2019，16（4）：548-555.
[2] Waddingham MT，Edgley AJ，Tsuchimochi H，et al. Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy [J]. World J Diabetes，2015，6（7）：943-960.
[3] Statsenko ME，Turkina SV，Shalaeva SS，et al. Impaired cardiac structural and functional parameters in patients with chronic heart failure and diabetic cardiac autonomic neuropathy [J]. Ter Arkh，2013，85（10）：23-28.
[4] Mercer TR，Dinger ME，Mattick JS. Long non-coding RNAs：insights into functions [J]. Nat Rev Genet，2009，10（3）：155-159.
[5] Jinek M，Doudna JA. A three-dimensional view of the molecular machinery of RNA interference [J]. Nature，2009，457（7228）：405-412.
[6] Bayne EH，Allshire RC. RNA-directed transcriptional gene silencing in mammals [J]. Trends Genet，2005，21（7）：370-373.
[7] Matrajt M. Non-coding RNA in apicomplexan parasites [J]. Mol Biochem Parasitol，2010，174（1）：1-7.
[8] Luo J，Liu H，Luan S，et al. Guidance of circular RNAs to proteins behavior as binding partners [J]. Cell Mol Life Sci，2019，7：22-37.
[9] Wang N，Yang C，Xie F，et al. Gadd45α：a novel diabetes-associated gene potentially linking diabetic cardiomyopathy and baroreflex dysfunction [J]. PLoS One，2012，7（12）：e49077.
[10] Zhou Q，Lv D，Chen P，et al. MicroRNAs in diabetic cardiomyopathy and clinical perspectives [J]. Front Genet，2014，5：185.
[11] Guo R，Nair S. Role of MicroRNA in Diabetic Cardiomyopathy：from Mechanism to Intervention [J]. Biochim Biophys Acta Mol Basis Dis，2017，1863（8）：2070-2077.
[12] Ambros V. The functions of animal microRNAs [J]. Nature，2004，431（7006）：350-355.
[13] Filipowicz W，Bhattacharyya SN，Sonenberg N. “Mechanisms of post-transcriptional regulation by microRNAs：are the answers in sight?” [J]. Nat Rev Genet，2008，9（2）：102-114.
[14] Zampetaki A，Kiechl S，Drozdov I，et al. Plasma microRNA profling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes [J]. Circ Res，2010， 107（6）：810-817.
[15] Giannella A，Radu CM，Franco L，et al. Circulating levels and characterization of microparticles in patients with diferent degrees of glucose tolerance [J]. Cardiovasc Diabetol，2017，16（1）：118-128.
[16] Jansen F，Wang H，Przybilla D，et al. Vascular endothelial microparticles-incorporated microRNAs are altered in patients with diabetes mellitus [J]. Cardiovasc Diabetol，2016，15（1）：49-59.
[17] Dai B，Li H，Fan J，et al. MiR-21 protected against diabetic cardiomyopathy induced diastolic dysfunction by targeting gelsolin [J]. Cardiovasc Diabetol，2018，17（1）：123-139.
[18] Huang ZP，Chen J，Seok HY，et al. MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress [J]. Circ Res，2013，112（9）：1234-1243.
[19] Tang Q，Len Q，Liu Z，et al. Overexpression of miR-22 attenuates oxidative stress injury in diabetic cardiomyopathy via Sirt 1 [J]. Cardiovasc Ther，2018，36（2）：e12318.
[20] Li X，Du N，Zhang Q，et al. MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy [J]. Cell Death Dis，2014，5：e1479.
[21] Pant T，Dhanasekaran A，Fang J，et al. Current status and strategies of long noncoding RNA research for diabetic cardiomyopathy [J]. BMC Cardiovasc Disord，2018，18（1）：197-206.
[22] Yang F，Qin Y，Wang Y，et al. LncRNA KCNQ1OT1 Mediates Pyroptosis in Diabetic Cardiomyopathy [J]. Cell Physiol Biochem，2018，50（4）：1230-1244.
[23] Zhang M，Gu H，Chen J，et al. Involvement of long noncoding RNA MALAT1 in the pathogenesis of diabetic cardiomyopath [J]. Int J Cardiol 2016，202：753-755.
[24] Rinn JL，Kertesz M，Wang JK，et al. Functional demarcation of active and silent chromatin domains in human hox loci by noncoding RNAs [J]. Cell，2007，129（7）：1311-1323.
[25] Gao L，Wang X，Guo S，et al. LncRNA HOTAIR functions as a competing endogenous RNA to upregulate SIRT1 by sponging miR-34a in diabetic cardiomyopathy [J]. J Cell，Physiol，2019，234（4）：4944-4958.